Internal Reference Number: FOI_9510
Date Request Received: 03/07/2026 00:00:00
Date Request Replied To: 17/07/2026 00:00:00
This response was sent via: By Email
Request Summary: Diffuse Large B Cell Lymphoma (DLBCL)
Request Category: Private Individuals
| Question Number 1: In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)? a. Of these patients, how many commenced treatment at your trust within the last 6 months? | |
| Answer To Question 1: 10 patients diagnosed and 6 commenced treatment within the last 6 months (Jan - June 2026). | |
| Question Number 2: In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments: • R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) • R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) • Pola-BR (polatuzumab vedotin with rituximab and bendamustine) • Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) • R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) • R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) • R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) • (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) • R-GemOX (rituximab, gemcitabine and oxaliplatin) • Axicabtagene ciloleucel • Tisagenlecleucel • Epcoritamab • Loncastuximab tesirine • Glofitamab • Any other SACT • Stem cell transplant or bone marrow transplant (autologous or allogeneic) • Glofitamab + GemOx (gemcitabine and oxaliplatin) | |
| Answer To Question 2: In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments: • R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) less than 5 • R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) less than 5 • Pola-BR (polatuzumab vedotin with rituximab and bendamustine) less than 5 • Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) less than 5 • R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) 0 • R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)0 • R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) 0 • (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) 0 • R-GemOX (rituximab, gemcitabine and oxaliplatin) less than 5 • Axicabtagene ciloleucel 0 • Tisagenlecleucel 0 • Epcoritamab 0 • Loncastuximab tesirine 0 • Glofitamab 0 • Any other SACT less than 5 • Stem cell transplant or bone marrow transplant (autologous or allogeneic) 0 • Glofitamab + GemOx (gemcitabine and oxaliplatin) less than 5 | |
| Question Number 3: In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL): • Axicabtagene ciloleucel (Yescarta) • Tisagenlecleucel • Pola-BR (polatuzumab vedotin with rituximab and bendamustine) • R-GemOX (rituximab, gemcitabine and oxaliplatin) • Stem cell transplant or bone marrow transplant (autologous or allogeneic) • Glofitamab + GemOx (gemcitabine and oxaliplatin) • Any other treatments | |
| Answer To Question 3: • Axicabtagene ciloleucel (Yescarta) 0 • Tisagenlecleucel 0 • Pola-BR (polatuzumab vedotin with rituximab and bendamustine) 0 • R-GemOX (rituximab, gemcitabine and oxaliplatin) 0 • Stem cell transplant or bone marrow transplant (autologous or allogeneic) 0 • Glofitamab + GemOx (gemcitabine and oxaliplatin) less than 5 • Any other treatments 0 | |
| Question Number 4: In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (BLBCL)? | |
| Answer To Question 4: 0 | |
| Question Number 5: . In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments: • CAR-T Therapy (E.g. Axicabtagene ciloleucel) • Stem cell transplant or bone marrow transplant (autologous or allogeneic) • Any other treatment | |
| Answer To Question 5: 0 patients referred elsewhere | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
